HIV vaccine 732461 + adjuvant

HIV vaccine 732461 + adjuvant is an investigational human immunodeficiency virus (HIV) vaccine candidate developed by GSK. The vaccine contains conserved regions of the HIV virus, specifically targeting the gag, pol, and nef proteins. It is formulated both with and without a proprietary GSK adjuvant system to enhance immunogenicity. The primary purpose of this candidate is to induce robust CD4+ T-cell immune responses against HIV antigens, which are assessed following vaccination. This approach leverages conserved HIV parts to overcome the high variability of the virus and includes adjuvants to boost the magnitude and persistence of the adaptive immune response. Clinical evaluation as of the available data includes early-phase, randomized, observer-blinded, dose-ranging studies in healthy, HIV-seronegative adults, focusing on safety, reactogenicity, and immunogenicity.

Brand names

gp120-NefTat + AS01B

Other names

gp120-NefTat/AS01Bbivalent HIV envelope glycoproteins + AS01B adjuvant